Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. It is engaged in the development of specialty care therapies to target a range of serious medical conditions. In addition, the company operates RegistryNXT, a web-based technology platform designed to collect patient clinical data related to the onset, progression, and treatment course of Gaucher, Fabry, MPS I, and Pompe diseases.

Employee Rating

HQCambridge, MA, US
Cybersecurity ratingBMore
Sanofi Genzyme was founded in 1981 and is headquartered in Cambridge, MA, US
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sanofi Genzyme

Bill Sibold

Bill Sibold

Executive Vice President and Head of Sanofi
Paul Hudson

Paul Hudson

Chief Executive Officer
Serge Weinberg

Serge Weinberg

Chairman of the Board of Directors
Manuela Buxo

Manuela Buxo

Senior Vice President, Region Head Europe
Olivier Charmeil

Olivier Charmeil

Executive Vice President, General Medicines
Natalie Bickford

Natalie Bickford

Executive Vice President, Chief People Officer
Show more

Sanofi Genzyme Office Locations

Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations
Cambridge, MA, US (HQ)
50 Binney St
Boston, MA, US
Copenhagen, DK
Show all (23)

Sanofi Genzyme Financials and Metrics

Summary Metrics

Founding Date


Sanofi Genzyme Revenue

Sanofi Genzyme's revenue was reported to be €10.43 b in FY, 2019 which is a 26.1% increase from the previous period.
EURFY, 2017FY, 2018FY, 2019



Revenue growth, %

Show all financial metrics

Sanofi Genzyme Operating Metrics

Sep, 2018Nov, 2020





Patents (US)



Show all operating metrics

Sanofi Genzyme Acquisitions / Subsidiaries

Company NameDateDeal Size
BioenvisionMay 29, 2007$345 m
AnorMEDOctober 17, 2006$580 m
BoneCare InternationalJuly 01, 2005$719 m
VerigenFebruary 09, 2005
ILEX Oncology, Inc.December 20, 2004$1 b
SangStatSeptember 10, 2003
BiomatrixDecember 18, 2000$738 m
PharmagenicsJune 16, 1997$28 m

Sanofi Genzyme Revenue Breakdown

Embed Graph

Sanofi Genzyme revenue breakdown by geographic segment: 11.8% from Emerging markets, 20.8% from Europe, 56.9% from United States and 10.4% from Rest of the world

Sanofi Genzyme Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Sanofi Genzyme Online and Social Media Presence

Embed Graph

Sanofi Genzyme Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Sanofi Genzyme News and Updates

Outlook on the Continuous and Semi-Continuous Bioprocessing Global Market to 2030 - Featuring AGC Biologics, Biogen and Sanofi Genzyme Among Others

Dublin, Sept. 22, 2021 (GLOBE NEWSWIRE) -- The "Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess, Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to…

Olipudase alfa demonstrated significant improvement in lung function and spleen volume in patients with ASMD

Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated significant improvement in lung function and spleen volume in patients with acid sphingomyelinase deficiency (ASMD). Results from two separate clinical trials of adult and pediatric patients were presented at th…

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

Additional positive results were announced from Part A of a pivotal Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). As previously reported, the trial met both of its co-primary and all key secondary endpoin…

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

Genetic testing and counseling through PD GENEration provides people with Parkinson's disease with detailed knowledge of their genetic status relative to key Parkinson's-related genes, ultimately empowering them to know more about their own disease. GBA, LRRK2 and SNCA are examples of genes associat…
Show more

Sanofi Genzyme Frequently Asked Questions

  • When was Sanofi Genzyme founded?

    Sanofi Genzyme was founded in 1981.

  • Who are Sanofi Genzyme key executives?

    Sanofi Genzyme's key executives are Bill Sibold, Paul Hudson and Serge Weinberg.

  • How many employees does Sanofi Genzyme have?

    Sanofi Genzyme has 9,904 employees.

  • What is Sanofi Genzyme revenue?

    Latest Sanofi Genzyme annual revenue is €10.4 b.

  • What is Sanofi Genzyme revenue per employee?

    Latest Sanofi Genzyme revenue per employee is €1.1 m.

  • Who are Sanofi Genzyme competitors?

    Competitors of Sanofi Genzyme include Biogen, Amgen and Amicus Therapeutics.

  • Where is Sanofi Genzyme headquarters?

    Sanofi Genzyme headquarters is located at 50 Binney St, Cambridge.

  • Where are Sanofi Genzyme offices?

    Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations.

  • How many offices does Sanofi Genzyme have?

    Sanofi Genzyme has 23 offices.